These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 19334042

  • 1. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
    Baldwin DS, Stein DJ, Dolberg OT, Bandelow B.
    Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
    [Abstract] [Full Text] [Related]

  • 2. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K, Andersen HF, Reines EH.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [Abstract] [Full Text] [Related]

  • 3. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 4. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
    Stein DJ, Kasper S, Andersen EW, Nil R, Lader M.
    Depress Anxiety; 2004 Feb; 20(4):175-81. PubMed ID: 15643634
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P, Andersen HF, Wade A.
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 14. Suicide rates in short-term randomized controlled trials of newer antidepressants.
    Hammad TA, Laughren TP, Racoosin JA.
    J Clin Psychopharmacol; 2006 Apr; 26(2):203-7. PubMed ID: 16633153
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
    Stein DJ, Andersen EW, Lader M.
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):33-8. PubMed ID: 16014329
    [Abstract] [Full Text] [Related]

  • 16. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH, Rush AJ, Wisniewski SR, Trivedi MH, Warden D, Fava M, Davis LL, Balasubramani GK, McGrath PJ, Berman SR.
    Drug Alcohol Depend; 2009 Jan 01; 99(1-3):248-60. PubMed ID: 18986774
    [Abstract] [Full Text] [Related]

  • 17. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P, Legault M.
    Depress Anxiety; 2008 Jan 01; 25(12):E173-81. PubMed ID: 19006260
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S.
    Psychiatry Res; 2009 Sep 30; 169(2):132-8. PubMed ID: 19709754
    [Abstract] [Full Text] [Related]

  • 19. Escitalopram in the treatment of generalized anxiety disorder.
    Baldwin DS, Nair RV.
    Expert Rev Neurother; 2005 Jul 30; 5(4):443-9. PubMed ID: 16026227
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
    Allgulander C, Jørgensen T, Wade A, François C, Despiegel N, Auquier P, Toumi M.
    Curr Med Res Opin; 2007 Oct 30; 23(10):2543-9. PubMed ID: 17825130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.